CHGCY
Price
$24.71
Change
+$0.56 (+2.32%)
Updated
Jul 25 closing price
Capitalization
49.42B
CMOPF
Price
$78.48
Change
+$14.11 (+21.92%)
Updated
Jul 25 closing price
Capitalization
827.91M
Interact to see
Advertisement

CHGCY vs CMOPF

Header iconCHGCY vs CMOPF Comparison
Open Charts CHGCY vs CMOPFBanner chart's image
Chugai Pharmaceutical
Price$24.71
Change+$0.56 (+2.32%)
Volume$45.46K
Capitalization49.42B
Cosmo Pharmaceuticals
Price$78.48
Change+$14.11 (+21.92%)
Volume$3
Capitalization827.91M
CHGCY vs CMOPF Comparison Chart in %
Loading...
CHGCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CMOPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHGCY vs. CMOPF commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHGCY is a StrongBuy and CMOPF is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (CHGCY: $24.71 vs. CMOPF: $78.48)
Brand notoriety: CHGCY and CMOPF are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: CHGCY: 34% vs. CMOPF: 2%
Market capitalization -- CHGCY: $49.42B vs. CMOPF: $827.91M
CHGCY [@Pharmaceuticals: Major] is valued at $49.42B. CMOPF’s [@Pharmaceuticals: Major] market capitalization is $827.91M. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHGCY’s FA Score shows that 0 FA rating(s) are green whileCMOPF’s FA Score has 1 green FA rating(s).

  • CHGCY’s FA Score: 0 green, 5 red.
  • CMOPF’s FA Score: 1 green, 4 red.
According to our system of comparison, both CHGCY and CMOPF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHGCY’s TA Score shows that 4 TA indicator(s) are bullish while CMOPF’s TA Score has 3 bullish TA indicator(s).

  • CHGCY’s TA Score: 4 bullish, 4 bearish.
  • CMOPF’s TA Score: 3 bullish, 0 bearish.
According to our system of comparison, CMOPF is a better buy in the short-term than CHGCY.

Price Growth

CHGCY (@Pharmaceuticals: Major) experienced а +6.55% price change this week, while CMOPF (@Pharmaceuticals: Major) price change was +21.92% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.43%. For the same industry, the average monthly price growth was +7.42%, and the average quarterly price growth was +13.00%.

Reported Earning Dates

CHGCY is expected to report earnings on Mar 27, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+3.43% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CHGCY($49.4B) has a higher market cap than CMOPF($828M). CMOPF has higher P/E ratio than CHGCY: CMOPF (68.49) vs CHGCY (21.46). CMOPF YTD gains are higher at: 17.265 vs. CHGCY (12.472). CHGCY has higher annual earnings (EBITDA): 458B vs. CMOPF (42.1M). CHGCY has more cash in the bank: 665B vs. CMOPF (222M). CMOPF has less debt than CHGCY: CMOPF (176M) vs CHGCY (215M). CHGCY has higher revenues than CMOPF: CHGCY (1.24T) vs CMOPF (104M).
CHGCYCMOPFCHGCY / CMOPF
Capitalization49.4B828M5,966%
EBITDA458B42.1M1,087,886%
Gain YTD12.47217.26572%
P/E Ratio21.4668.4931%
Revenue1.24T104M1,196,154%
Total Cash665B222M299,550%
Total Debt215M176M122%
FUNDAMENTALS RATINGS
CHGCY vs CMOPF: Fundamental Ratings
CHGCY
CMOPF
OUTLOOK RATING
1..100
348
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
20
Undervalued
PROFIT vs RISK RATING
1..100
10095
SMR RATING
1..100
4154
PRICE GROWTH RATING
1..100
6059
P/E GROWTH RATING
1..100
5195
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CMOPF's Valuation (20) in the null industry is somewhat better than the same rating for CHGCY (79). This means that CMOPF’s stock grew somewhat faster than CHGCY’s over the last 12 months.

CMOPF's Profit vs Risk Rating (95) in the null industry is in the same range as CHGCY (100). This means that CMOPF’s stock grew similarly to CHGCY’s over the last 12 months.

CHGCY's SMR Rating (41) in the null industry is in the same range as CMOPF (54). This means that CHGCY’s stock grew similarly to CMOPF’s over the last 12 months.

CMOPF's Price Growth Rating (59) in the null industry is in the same range as CHGCY (60). This means that CMOPF’s stock grew similarly to CHGCY’s over the last 12 months.

CHGCY's P/E Growth Rating (51) in the null industry is somewhat better than the same rating for CMOPF (95). This means that CHGCY’s stock grew somewhat faster than CMOPF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHGCYCMOPF
RSI
ODDS (%)
Bullish Trend 1 day ago
65%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
67%
Bullish Trend 1 day ago
50%
Momentum
ODDS (%)
Bullish Trend 1 day ago
76%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
22%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
22%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
72%
Bullish Trend 1 day ago
23%
Advances
ODDS (%)
Bullish Trend 10 days ago
72%
N/A
Declines
ODDS (%)
Bearish Trend 12 days ago
77%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
73%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
26%
View a ticker or compare two or three
Interact to see
Advertisement
CHGCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CMOPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CHDEX14.070.02
+0.14%
Cullen High Dividend Equity Retail
NBSTX52.07N/A
N/A
Neuberger Berman Sustainable Equity Tr
AIMOX17.74N/A
N/A
AQR International Momentum Style I
MFRLX50.18N/A
N/A
MFS Research R1
SHDIX10.06N/A
N/A
American Beacon Shapiro SMID Cap Eq R5

CHGCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHGCY has been loosely correlated with DSNKY. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CHGCY jumps, then DSNKY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHGCY
1D Price
Change %
CHGCY100%
+2.32%
DSNKY - CHGCY
38%
Loosely correlated
-1.01%
OTSKY - CHGCY
32%
Poorly correlated
+2.15%
OPHLY - CHGCY
32%
Poorly correlated
-0.82%
CHGCF - CHGCY
28%
Poorly correlated
+0.43%
DSKYF - CHGCY
23%
Poorly correlated
-2.61%
More

CMOPF and

Correlation & Price change

A.I.dvisor tells us that CMOPF and GSK have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CMOPF and GSK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMOPF
1D Price
Change %
CMOPF100%
+21.92%
GSK - CMOPF
22%
Poorly correlated
-0.68%
NVS - CMOPF
21%
Poorly correlated
+0.20%
CHGCY - CMOPF
7%
Poorly correlated
+2.32%
DSNKY - CMOPF
5%
Poorly correlated
-1.01%
CSPCY - CMOPF
4%
Poorly correlated
+1.05%
More